Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Blosozumab · 1 trial · 1 indication
The mean maximum observed drug concentration of Blosozumab during 1 dosing interval was reported.
The mean area under the concentration of Blosozumab versus time curve during 1 dosing interval was reported.
| Arm | Type | Description |
|---|---|---|
| Blosozumab | EXPERIMENTAL | Weekly SC injections of blosozumab for 6 weeks. |
| Name | Type | Description |
|---|---|---|
| Blosozumab | DRUG | Administered subcutaneously |
Inclusion Criteria: * Part A: Overtly healthy PMP females * Part B: PMP women who are currently taking oral bisphosphonates * Have a body mass index (BMI) at screening of 19.0 to 35.0 kilogram per square meter (kg/m\^2) Exclusion Criteria: * Show evidence of human immunodeficiency virus (HIV) inf...
Blosozumab is an investigational small molecule being studied for the treatment of postmenopausal osteoporosis. It is intended for use in postmenopausal female participants with this condition. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Blosozumab is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate the drug's safety and efficacy in postmenopausal women with osteoporosis.
Blosozumab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved for commercial use. The Phase 1 trial has been completed, and the drug remains under investigation for postmenopausal osteoporosis.
Blosozumab has one completed Phase 1 clinical trial registered as NCT02109042, titled 'A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants.' The trial enrolled 15 participants in the United States and included healthy volunteers aged 60 years and older.
Yes, Blosozumab is also known as LY2541546. The clinical trial NCT02109042 uses this alternative name in its title, referring to the same investigational drug being studied for postmenopausal osteoporosis.